SEC Comment Letter 0000000000-23-007107 to Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc.
Date: July 5, 2023 · CIK: 0001736243 · Accession: 0000000000-23-007107
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273015
Letter
United States securities and exchange commission logo July 5, 2023 David Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Re:Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 29, 2023 File No. 333-273015 Dear David Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey D. Cohan
Show Raw Text
United States securities and exchange commission logo
July 5, 2023
David Luci
President and Chief Executive Officer
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, New York 10305
Re:Acurx Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed June 29, 2023
File No. 333-273015
Dear David Luci:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey D. Cohan